منابع مشابه
Engineering Exosomes for Cancer Therapy
There remains an urgent need for novel therapeutic strategies to treat metastatic cancer, which results in over 8 million deaths annually worldwide. Following secretion, exosomes are naturally taken up by cells, and capable of the stable transfer of drugs, therapeutic microRNAs and proteins. As knowledge of the biogenesis, release and uptake of exosomes continues to evolve, and thus also has in...
متن کاملSignificance of exosomes in COVID-19 pathogenesis and therapy
Exosomes are lipid bilayer-enclosed nano-sized vesicles, which carry various biomolecules including proteins, lipids, and microRNAs. SARS-CoV-2-loaded exosomes can be entered into the susceptible host cells, and transported viral components which are associated with viral particles intercellular transmission and spread of infection. Over-stimulation of the immune system followed by excessive pr...
متن کاملResistance to Anti-VEGF Therapy Mediated by Autocrine IL6/STAT3 Signaling and Overcome by IL6 Blockade.
Anti-VEGF therapies benefit several cancer types, but drug resistance that limits therapeutic response can emerge. We generated cell lines from anti-VEGF-resistant tumor xenografts to investigate the mechanisms by which resistance develops. Of all tumor cells tested, only A431 (A431-V) epidermoid carcinoma cells developed partial resistance to the VEGF inhibitor aflibercept. Compared with the p...
متن کاملCo-treatment by docetaxel and vinblastine breaks down P-glycoprotein mediated chemo-resistance
Objective(s): Chemoresistance remains the main causes of treatment failure and mortality in cancer patients. There is an urgent need to investigate novel approaches to improve current therapeutic modalities and increase cancer patients' survival. Induction of drug efflux due to overexpression of P-glycoproteins is considered as an important leading cause of multidrug resistance...
متن کاملExosomes in stroke pathogenesis and therapy
Introduction Stroke is one of leading causes of death and disability worldwide (1). Since it was approved by the FDA in 1996, tissue plasminogen activator (tPA) has become the only treatment for patients presenting with stroke within 4.5 hours of onset (2–5). Recently, endovascular thrombectomy has been shown to extend the therapeutic window for patients to within 12 hours after stroke onset by...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Molecular Cancer
سال: 2019
ISSN: 1476-4598
DOI: 10.1186/s12943-019-0970-x